Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
3
Neutral
7
Bullish
4
Bearish
4
Neutral
7
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Thyrocare Technologies Limited is a leading Indian diagnostic company, primarily focused on providing affordable and quality diagnostic services across the country. With a vast network of authorized service providers and laboratories, it offers a wide range of tests, including preventive and wellness profiles under the 'Aarogyam' brand.
In recent developments, Thyrocare reported an 18% YoY growth in revenue and 38% YoY growth in EBITDA for Q3 FY26, showcasing strong financial performance and operational scale. Franchise revenue and partnership segments also showcased notable growth.
Thyrocare has expanded its laboratory network, including new labs in Karnataka and Himachal Pradesh, further strengthening its pan-India presence and enhancing processing capacities. Additionally, they have maintained 100% NABL accreditation, emphasizing their commitment to quality.
Madhuri Dixit has been onboarded as Thyrocare's brand ambassador to boost brand visibility and association with excellence. The company is focusing on deepening its reach through franchise expansion and partnerships, including international ventures in Tanzania.
Healthcare Services
Healthcare Service Provider
8,526 Cr
Low Risk
52.3
58.9
2.4
16.6
578.05
316.76
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Thyrocare Technologies Ltd (THYROCARE) is currently trading at 533.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Thyrocare Technologies Limited is a leading Indian diagnostic company, primarily focused on providing affordable and quality diagnostic services across the country. With a vast network of authorized service providers and laboratories, it offers a wide range of tests, including preventive and wellness profiles under the 'Aarogyam' brand. In recent developments, Thyrocare reported an 18% YoY growth in revenue and 38% YoY growth in EBITDA for Q3 FY26, showcasing strong financial performance and operational scale. Franchise revenue and partnership segments also showcased notable growth. Thyrocare has expanded its laboratory network, including new labs in Karnataka and Himachal Pradesh, further strengthening its pan-India presence and enhancing processing capacities. Additionally, they have maintained 100% NABL accreditation, emphasizing their commitment to quality. Madhuri Dixit has been onboarded as Thyrocare's brand ambassador to boost brand visibility and association with excellence. The company is focusing on deepening its reach through franchise expansion and partnerships, including international ventures in Tanzania.
Over the past 52 weeks, Thyrocare Technologies Ltd has traded between a low of ₹316.76 and a high of ₹578.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Thyrocare Technologies Ltd has a market capitalization of approximately 8,525.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Thyrocare Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 52.29 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 8,525.69 Cr, Thyrocare Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Thyrocare Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Thyrocare Technologies Ltd is 52.29. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Consolidated revenue was ₹216.53 crore (+22% YoY), EBITDA ₹75.36 crore (+49% YoY) and PAT ₹47.90 crore (+82% YoY).
Thyrocare reported a 36.7% year-on-year increase in net profit to ₹26.1 crore, a 19.3% rise in revenue to ₹182 crore, and a 46.7% surge in EBITDA to ₹58.3 crore for Q3 FY26.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1287.40 | 13,211 Cr | 76.38 | 13.80 | 0.16 | 18.07 | 19.27 | 11.48 | ||
525.05 | 10,894 Cr | 57.33 | 7.20 | 0.95 | 12.56 | 16.25 | 8.94 | ||
534.50 | 8,526 Cr | 52.29 | 16.63 | 2.61 | 27.85 | 33.90 | 21.79 | ||
717.60 | 7,133 Cr | 92.83 | 6.39 | 0.00 | 6.88 | 13.18 | 5.22 | ||
539.25 | 1,749 Cr | 17.24 | 1.78 | 0.37 | 10.35 | 10.42 | 5.56 | ||
267.50 | 1,395 Cr | 43.33 | 5.70 | 0.19 | 13.15 | 14.38 | 7.01 | ||
665.35 | 1,300 Cr | 18.72 | 9.21 | 0.00 | 49.21 | 65.70 | 27.21 | ||
| Median: 7 Co. | — | 539.25 | 7,133 Cr | 52.29 | 7.20 | 0.19 | 13.15 | 16.25 | 8.94 |
Dividend Taxation
Thyrocare advised shareholders that the Board has recommended a final dividend of Rs.7.00 per share for FY2025‑26 (subject to AGM approval on June 30, 2026; record date June 23, 2026) and detailed applicable TDS rates, documentation and procedures.
Dividend TDS
Thyrocare notified shareholders that the Board recommended a final dividend of Rs.7.00 per share for FY2025-26 (subject to AGM approval on June 30, 2026; record date June 23, 2026) and provided TDS rates and required documentation for dividend payouts.
